A practical guide for pharma leaders deciding whether to build their statistical computing environment (SCE) on-premise or in the cloud. The piece argues that while on-prem still suits stable, predictable workloads and large legacy datasets, modern SCEs are no longer stable workloads — they need elastic compute, multi-language support, and AI/ML-ready hardware that cloud delivers natively. It addresses the security objection head-on (citing Gartner's finding that 99% of cloud security failures are customer misconfigurations, not platform weaknesses), highlights how cloud democratizes access to the same infrastructure powering Novo Nordisk and Eli Lilly's NVIDIA partnerships, and lands on a pragmatic recommendation: build on cloud-native patterns (containers, IaC, automated deployments) regardless of where you deploy today, so a future migration is incremental rather than a rewrite. Hybrid is positioned as the enterprise default, with 90% of organizations expected to adopt it by 2027.